PDCD1 and melanoma: Several TIM‐3 inhibitors, such as TQB2618, bc3402, and cobolimab, are undergoing clinical trials in combination with PD‐1/PD‐L1 inhibitors for the treatment of advanced squamous cell carcinoma of the head and neck, liver cancer, non‐small cell lung cancer, and melanoma, with studies progressing at various stages.